Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Immunicum AB Receives Clearance to Start Second Clinical Study in 12 Liver Cancer Patients


Monday, 22 Jul 2013 06:38am EDT 

Immunicum AB announced that the Company has received clearance by the Swedish Medical Products Agency to start its second clinical study. The study will be conducted in 12 liver cancer patients at Sahlgrenska University Hospital in Gothenburg. The liver cancer study will be completed in approximately two years and evaluates both the tolerability and efficacy of the treatment. Parallel to this, the Company will complete its ongoing phase I/II-study in renal cancer and intensify the planning of an upcoming phase II-trial.